Sort   by:  
 Page size 
MetabolomicsBiomarker Discovery in Oral Cancer (OSMF & OSCC) and its severity

Oral squamous cell carcinoma (OSCC) is frequently the outcome of oral submucous fibrosis (OSMF), a common possibly premalignant disease. In our study, a cohort of 50 patients with OSCC and OSMF, along with 50 healthy controls, was analyzed to identify significant metabolic differences between the...

2024-10-23 | MTBLS11009 | MetaboLights
MetabolomicsBiomarker Discovery in Knee Osteoarthritis (I)
Not available
ORGANISM(S): Homo sapiens 
ST000020 | MetabolomicsWorkbench
MetabolomicsInvestigate the False Discovery in Biomarker Research Using LC-HRMS based Untargeted Metabolomics Profiling
Not available
ORGANISM(S): Homo sapiens 
ST001132 | MetabolomicsWorkbench
MetabolomicsSerum metabolomic profiles for distinguishing lung cancer from pulmonary tuberculosis: identification of rapid and noninvasive biomarker

BACKGROUND: Pulmonary tuberculosis (TB) and lung cancer (LC) have similar clinical symptoms and atypical imaging findings which are easily misdiagnosed. There is an urgent need for a noninvasive, rapid and accurate biomarker for distinguishing LC from TB.

METHODS:

2024-01-16 | MTBLS6990 | MetaboLights
MetabolomicsLC-HRMS based plasma metabolomics analysis for biomarker discovery of neuroblastoma: 3-O-methyldopa is a new biomarker of poor prognosis of metastatic disease
Not available
ORGANISM(S): Homo sapiens 
ST002238 | MetabolomicsWorkbench
MetabolomicsDIAMetAlyzer allows automated false-discovery rate-controlled analysis for data-independent acquisition in metabolomics
The extraction of meaningful biological knowledge from high-throughput mass spectrometry data relies on limiting false discoveries to a manageable amount. For targeted approaches in metabolomics a main challenge is the detection of false positive metabolic features in the low signal-to-noise ranges ...
2022-09-05 | MTBLS1108 | MetaboLights
MetabolomicsUntargeted LC-HRMS Based-Plasma Metabolomics Reveals 3-O-Methyldopa as a New Biomarker of Poor Prognosis in High-Risk Neuroblastoma
Neuroblastoma (NB) is the most common extracranial malignant tumor in children. Although the survival rate of NB has improved over the years, the outcome of NB still remains poor for over 30% of cases. A more accurate risk stratification remains a key point in the study of NB and the availability of...
2023-07-14 | MTBLS4294 | MetaboLights
MetabolomicsDiscovery and validation of potential serum biomarkers for heart failure by untargeted metabolomics

Detection of biomarkers was extremely important for the early diagnosis, prognosis and therapy optimization of diseases. The purpose of this study was to investigate the differences in serum metabolites between patients with heart failure (HF) and healthy controls (HC), and to diagnose HF qualita...

2025-07-18 | MTBLS9586 | MetaboLights
MetabolomicsMass Spectrometry-based Proteomic and Metabolomic profiling of serum samples for discovery and validation of Tuberculosis diagnostic biomarker signature
Not available
ORGANISM(S): Homo sapiens 
ST002428 | MetabolomicsWorkbench
MetabolomicsDiscovery of urinary biomarkers to discriminate between exogenous and semi-endogenous thiouracil in cattle (Cow samples)
In the European Union, the use of thyreostats for animal fattening purposes has been banned because of their carcinogenic and teratogenic effects, whereby any residues in derived food products may hold a risk for human health. In this regard, potential abuse is monitored by targeted analysis of thyr...
2018-02-22 | MTBLS561 | MetaboLights
Sort   by:  
 Page size